Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM7F2VG)

Drug Name
SA-237 Drug Info
Synonyms Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
Indication
Disease Entry ICD 11 Status REF
Encephalopathy 8E47 Phase 3 [1]
Neuromyelitis optica 8A43 Phase 3 [2]
Rheumatoid arthritis FA20 Phase 3 [3]
Cross-matching ID
TTD Drug ID
DM7F2VG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN; IL6RB_HUMAN Antagonist [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin 6 receptor (IL6R) DTT IL6R 6.42 5.564 5.031 5.404
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Encephalopathy
ICD Disease Classification 8E47
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 6 receptor (IL6R) DTT IL6R; IL6ST 4.80E-03 1.08 1.67
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health.
4 IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.